Extended Follow-up With Daratumumab-Based Regimen in Newly Diagnosed Myeloma
Posted: Thursday, January 6, 2022
The phase II GRIFFIN trial found that treatment with the monoclonal antibody daratumumab plus lenalidomide, bortezomib, and dexamethasone (RVd), used in conjunction with autologous stem cell transplantation, may result in “deep and durable” responses for patients with transplant-eligible newly diagnosed multiple myeloma, according to updated results presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 79). Peter M. Voorhees, MD, of the Levine Cancer Institute, Charlotte, North Carolina, and colleagues concluded that, besides stringent complete response and measurable residual disease (MRD) negativity (10-5 and 10-6) rates, treatment with the four-drug regimen also demonstrated a positive trend for progressive-free survival.
“These results support the use of daratumumab/RVd induction/consolidation and [daratumumab plus lenalidomide] maintenance in transplant-eligible patients with newly diagnosed multiple myeloma,” the authors concluded.
In this trial, the authors enrolled 207 patients with newly diagnosed multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation. Patients received either RVd (103 patients) or daratumumab plus RVd (104 patients).
After 24 months of maintenance therapy, patients treated with daratumumab plus RVd had higher rates of stringent complete response (66.0%) than those who received RVd alone (47.4%). In the intent-to-treat population, MRD negativity (10-5) rates were also higher for patients treated with daratumumab plus RVd (64.4%) than in the RVd-alone cohort (30.1%), as well as for rates of MRD negativity (10-6; 35.6% vs. 14.6%, respectively).
The authors estimated that the 36-month progression-free survival rate was 88.9% for patients treated with daratumumab plus RVd and 81.2% for those who received RVd alone. In total, 14 patients died, 7 in both cohorts. The authors reported no new safety concerns in the extended follow-up.
Disclosure: For full disclosures of the study authors, visit ash.com.
